Boston is arguably the world’s greatest life sciences cluster. But what’s the long-term outlook—and how can it stay on top 20 years from now? These questions are at the heart of an evening forum that Xconomy is hosting on October 4 called Boston Life Sciences 2032.
The lineup for this intimate discussion already featured some of the region’s outstanding thinkers on the subject, from both the investing and biotech company perspectives: Deborah Dunsire, CEO of Millennium: The Takeda Oncology Company; Cubist Pharmaceuticals CEO Michael Bonney; Noubar Afeyan, managing partner and CEO of Flagship Ventures; and John Mendlein, executive chairman and CEO of aTyr Pharma and vice chairman Fate Therapeutics.
Now, we are extremely pleased to announce another great addition to this power-packed assembly, this time from the academic, medical, healthcare, and Big Pharma arenas. The newcomer is Dennis Ausiello, chief of medicine at Massachusetts General Hospital. It is hard to think of a person with such a broad and deep range of expertise that bears on the future of Boston area life sciences as Ausiello has. In addition to his MGH role, he is also professor of clinical medicine at Harvard Medical School, and chief scientific officer of Partners Healthcare. Oh, by the way, he is also on the board of directors of the Broad Institute and Pfizer, one of the world’s largest pharmaceutical companies (and believe us, that is just a taste of his incredible resume).
Here’s how the evening will shape up. First, Dunsire, whose company is hosting the event in its beautiful auditorium, will provide a short keynote talk giving her perspective on the challenges and promises of maintaining Boston’s life sciences mojo. Then, Bonney, Afeyan, and Ausiello will take the stage for a highly interactive discussion, among themselves and you, the audience, that will be moderated and facilitated by Mendlein, himself one of the most thoughtful and dynamic commentators of life sciences writ large.
In short, it should be a fantastic evening—but there’s a catch. Ticket sales are already off the charts—and there are only a few seats left. We are exploring overflow opportunities, but the best strategy is to get your ticket now. Here’s where to register and find out more details.
We hope to see you on October 4.
